IAP7 Hec'd PCTIPTO 08 MAY 2006

	EV524615183US	8 May	2006							
	Express Mail Label Number		Deposit							
Form PTC	D-1390-MOD U. S.	Department of Commerce Patent and Trademark Office	ATTORNEY'S DOCKET NUMBER							
(REV 10-9		Separate Roll Continue Continu	33474-US-PCT							
	TRANSMITTAL LETTER TO 1	U.S. APPLICATION NO. (If known, see 37 CFR 1.5)								
	DESIGNATED/ELECTED O CONCERNING A FILING UN	10/578469								
	RNATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED							
	EP2004/012567 OF INVENTION	6 November 2003 (06.11.03)								
	ING AND CHARACTERIZATION OF 5	FLANKING REGIONS OF A HUMA	AN AGGRECANASE-1 GENE							
APPL	ICANT(S) FOR DO/EO/US IDRIKA SAIDAPET KUMAR									
Applica	ant herewith submits to the United States D	esignated/Elected Office (DO/EO/US) the	ne following items and other information:							
. 57										
1. ⊠ 2. □	This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.									
3.										
4. 🗵	A proper Demand for International Prelin date.									
5. 🛛	A copy of the International Application as		od Russey)							
	 a. is transmitted herewith (required only if not transmitted by the International Bureau). b. has been transmitted by the International Bureau. (See Form PCT/IB/308) 									
6.		n was filed in the United States Receiving into English (35 LLS C. 371(c)(2))	g Office (RO/US).							
6. <u> </u>										
	a. are transmitted herewith (requireb. have been transmitted by the Interest	d only if not transmitted by the Internation	onal Bureau).							
	c. have not been made; however, to	he time limit for making such amendmer	nts has NOT expired.							
8.	d. have not been made and will not have not been made and will not a translation of the amendments to the c		871 (c)(3))							
9.	A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)). An executed Declaration and Power of Attorney (original or copy) (35 U.S.C. 371(c)(4)).									
10.	A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).									
ltems :	11. to 16. below concern document(s) or	information included								
_										
		An Information Disclosure Statement under 37 CFR 1.97 and 1.98.								
12.	An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.									
13. ⊠ □	A FIRST preliminary amendment. A SECOND or SUBSEQUENT preliminary amendment.									
14. 🛛	An Application Data Sheet under 37 CFF	R 1.76.								
15.	A substitute specification.									
16.	A change of power of attorney and/or ad-	dress letter.								
17.	A computer-readable form of the sequen	A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821-1.825.								
18. 🗌	A second copy of the published Internation	A second copy of the published International Application under 35 U.S.C. 154(d)(4).								
19. 🗆	A second copy of the English language to	ranslation of the International application	n under 35 U.S.C. 154(d)(4).							
20 I	Other items or information: Unsigned De	relaration: nectoord								

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

U.S. APPLICATIONING	. (#known, sab st CFF11.		NATIONAL APPLICATION NO. 7/EP2004/012567		ATTORNEYS D	DOCKET NUMBER				
The following fe	es are submitted:					CAL	CULATIO	NS PTO USE		
21. 🛛 Basi	c national fee				\$300	ONLY				
22. Examination Fee If International preliminary examination report was prepared by USPTO and all claims satisfy provisions of PCT Article 33(1)-(4)										
All other situations										
23. Search fee If Search fee (37 CFR 1.445(a)(2)) has been paid on the international application to the USPTO as an International Searching Authority. \$ If International Search Report was prepared and provided to the Office. \$400 All other situations. \$										
		TOTAL OF	21, 22 AND 23 =			\$	900			
Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.										
Total Sheets	Extra sheets		ch additional 50 or fraction of the distribution of the distributi	on	RATE					
44 - 100 =	/50 =		0	X :	\$ 250	\$				
Surcharge of \$130 for furnishing the oath of declaration later than months from the earliest claimed priority date (37 CFR 1.492(e)).										
CLAIMS Total claims	NUMBI 25	ER FILED - 20 =	NUMBER EXTRA 5	X \$	RATE 50	\$. 250			
Independent cla		-3 =	8	X \$	200	\$	1,600			
MULTIPLE DEPENDENT CLAIM(S) (if applicable) + \$ 360							0.750			
TOTAL OF ABOVE CALCULATIONS = Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be							2,750			
filed (Note 37 CFR 1.9, 1.27, 1.28).										
SUBTOTAL =							2,750			
Processing fee of \$130 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(f)).										
					NAL FEE =	\$	2,750			
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40 per property +										
TOTAL FEES ENCLOSED =							2,750			
							mount to refunded	\$		
							charged	\$		
b. 🛛 Please	 a. A check in the amount of \$ to cover the above fees is enclosed. b. Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$2,750 to cover the above fees. A duplicate copy of this form is enclosed. 									
c. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 19-0134 in the name of Novartis.										
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.										
Send all correspondence to the address associated with Customer No. 001095, which is currently:										
Novartis Corporate Intellectual Property One Health Plaza, Building 104 East Hanover, NJ 07936-1080 Thomas V. Digby for Applicant Reg. No. L0242 (617) 871-3224										